Zynex

ZYXI · NASDAQ

Price unavailable right now.

No price history for this range.

ZYXI analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Aug 28, 2025

Bull case

Zynex Inc. reported a 16% year-over-year growth in orders for Fiscal Year 2024, indicating a robust demand for its electrotherapy and pain management products. The company's focus on enhancing revenue per sales representative to $1 million, alongside positive clinical study results for its laser-based system, positions Zynex strongly within the medical device sector as a leader in non-opioid pain management solutions. Additionally, a projected annual savings of approximately $35 million from expense reductions in the second half of 2025 and the first quarter of 2025 further enhances the company's financial outlook, potentially leading to increased profitability and market share growth.

Bear case

Zynex Inc has indicated a significant downturn in its financial outlook, with projected Q1 2025 sales of at least $30 million, highlighting a decline of 37% year-over-year and a 35% sequential decrease. The company's Q4 2024 total revenue was reported at $46 million, reflecting a 3% decline year-over-year and a notable shortfall against earlier projections. Furthermore, Zynex's earnings report showed an EPS loss of $0.30, compounded by reduced sales expectations for 2025, which are now modeled at $140 million, representing a 28% decrease year-over-year, thus underscoring concerns about operational visibility and ongoing business challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.